ATE303156T1 - Verwendung von gnrh-analogue zur behandlung der harninkontinenz - Google Patents
Verwendung von gnrh-analogue zur behandlung der harninkontinenzInfo
- Publication number
- ATE303156T1 ATE303156T1 AT01975948T AT01975948T ATE303156T1 AT E303156 T1 ATE303156 T1 AT E303156T1 AT 01975948 T AT01975948 T AT 01975948T AT 01975948 T AT01975948 T AT 01975948T AT E303156 T1 ATE303156 T1 AT E303156T1
- Authority
- AT
- Austria
- Prior art keywords
- urinary incontinence
- gnrh analogue
- treat urinary
- gnrh
- analogue
- Prior art date
Links
- 206010046543 Urinary incontinence Diseases 0.000 title abstract 2
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 title 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 title 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 abstract 1
- 206010060800 Hot flush Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001850 reproductive effect Effects 0.000 abstract 1
- 230000009758 senescence Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00811011 | 2000-10-30 | ||
| PCT/CH2001/000636 WO2002036144A1 (en) | 2000-10-30 | 2001-10-26 | Gnrh analogues for treatment of urinary incontinence |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE303156T1 true ATE303156T1 (de) | 2005-09-15 |
Family
ID=8174999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01975948T ATE303156T1 (de) | 2000-10-30 | 2001-10-26 | Verwendung von gnrh-analogue zur behandlung der harninkontinenz |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7498303B2 (de) |
| EP (1) | EP1330257B1 (de) |
| JP (1) | JP2004512369A (de) |
| AT (1) | ATE303156T1 (de) |
| AU (1) | AU2001295359A1 (de) |
| BR (1) | BR0115067A (de) |
| CA (1) | CA2427731A1 (de) |
| DE (1) | DE60113142T2 (de) |
| WO (1) | WO2002036144A1 (de) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US7812049B2 (en) | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
| GT200500315A (es) * | 2004-11-02 | 2006-06-06 | Formas de dosificacion oral solidas que contienen una dosis baja de estradiol | |
| CN101189026A (zh) * | 2005-06-01 | 2008-05-28 | 辉瑞产品公司 | 用于治疗尿失禁的疫苗组合物及方法 |
| EP1967202A1 (de) * | 2007-03-05 | 2008-09-10 | AEterna Zentaris GmbH | Verwendung von LHRH-Antagonisten zur Behandlung von Symptomen der unteren Harnwege, insbesondere Blasen- und/oder Detrusorhyperaktivität |
| EP2266567A1 (de) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Pharmazeutische Zubereitung enthaltend Cetrorelix und PDE V Hemmern zur Behandlung von Sexualhormon abhängige Erkrankungen |
| EP2266568A1 (de) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Pharmazeutische Zubereitung enthaltend LHRH-Antagonisten und PDE V Hemmern zur Behandlung von Sexualhormon abhängigen Erkrankungen |
| EP2558076B1 (de) * | 2010-04-15 | 2014-12-24 | Bayer Intellectual Property GmbH | Niedrig dosierte feste arzneiform zur hormonersatztherapie |
| AU2011252763B2 (en) * | 2010-05-14 | 2012-12-20 | Charlotte L. Keating | A method of treatment and diagnosis |
| US8633178B2 (en) | 2011-11-23 | 2014-01-21 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US8871259B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Techniques and systems for treatment of neuropathic pain and other indications |
| US8871258B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment and prevention of learning and memory disorders |
| US8871255B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment of skin and soft tissue infection with nitric oxide |
| US8871256B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and systems for treatment of inflammatory diseases with nitric oxide |
| US8871257B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery |
| US8871261B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Cancer treatments and compositions for use thereof |
| US8871254B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system |
| US8871260B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and compositions for muscular and neuromuscular diseases |
| US8871262B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Compositions and methods for treatment of osteoporosis and other indications |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20140271938A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
| US9314423B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Hair treatment systems and methods using peptides and other compositions |
| US9387159B2 (en) | 2013-03-13 | 2016-07-12 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
| US20140271731A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
| US9339457B2 (en) | 2013-03-13 | 2016-05-17 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
| US9314433B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
| US9295636B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
| US9393265B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
| US9849160B2 (en) | 2013-03-13 | 2017-12-26 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
| US9393264B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
| US9241899B2 (en) | 2013-03-13 | 2016-01-26 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
| US9750787B2 (en) | 2013-03-13 | 2017-09-05 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
| US9314422B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
| US9320706B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
| US9295637B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Compositions and methods for affecting mood states |
| US9320758B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
| US9314417B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
| US9724419B2 (en) | 2013-03-13 | 2017-08-08 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
| US9295647B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
| US9687520B2 (en) | 2013-03-13 | 2017-06-27 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
| EP3145489A1 (de) | 2014-05-22 | 2017-03-29 | TherapeuticsMD, Inc. | Natürliche kombinierte hormonersatzformulierungen und therapien |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| HUE058207T2 (hu) * | 2017-01-31 | 2022-07-28 | Veru Inc | Készítmények és módszerek gonadotropin felszabadító hormon (GNRH) antagonisták elnyújtott idejû felszabadítására |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5434136A (en) * | 1990-12-14 | 1995-07-18 | Mathias; John R. | Treatment of motility disorders with a GNRH analog |
| US5340585A (en) * | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
| US5211952A (en) * | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
| US5340805A (en) * | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Danazol for treatment of urinary incontinence |
| US5681817A (en) * | 1994-02-04 | 1997-10-28 | The Medical College Of Hampton Roads | Treatment of ovarian estrogen dependent conditions |
| AUPN366795A0 (en) * | 1995-06-20 | 1995-07-13 | Peptide Technology Limited | Formulation for preventing reproductive function |
| US5789442A (en) * | 1996-01-18 | 1998-08-04 | Schering Aktiengesellschaft | Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents |
| NZ334236A (en) * | 1996-08-30 | 2000-06-23 | Peptech Ltd | Composition comprising GnRH, lecithin and stearin |
| US6416778B1 (en) * | 1997-01-24 | 2002-07-09 | Femmepharma | Pharmaceutical preparations and methods for their regional administration |
| US6051558A (en) * | 1997-05-28 | 2000-04-18 | Southern Biosystems, Inc. | Compositions suitable for controlled release of the hormone GnRH and its analogs |
| WO1999020647A1 (fr) * | 1997-10-17 | 1999-04-29 | Mochida Pharmaceutical Co., Ltd. | Remede contre les hysteromyomes, contenant du dienogeste comme principe actif |
| CN1307481A (zh) | 1998-04-27 | 2001-08-08 | 普雷西斯药品公司 | 用于治疗热潮红和男子女性型乳房的方法 |
| US6586000B2 (en) * | 1999-12-16 | 2003-07-01 | Dermatrends, Inc. | Hydroxide-releasing agents as skin permeation enhancers |
| GB0015246D0 (en) * | 2000-06-22 | 2000-08-16 | Astrazeneca Ab | Method for the treatment of urinary incontinence |
| EP1466625A4 (de) * | 2001-12-28 | 2007-07-18 | Takeda Pharmaceutical | Vorbeugungs-/heilmittel für blasenstörungen |
-
2001
- 2001-10-26 DE DE60113142T patent/DE60113142T2/de not_active Expired - Lifetime
- 2001-10-26 AT AT01975948T patent/ATE303156T1/de not_active IP Right Cessation
- 2001-10-26 JP JP2002538955A patent/JP2004512369A/ja not_active Withdrawn
- 2001-10-26 WO PCT/CH2001/000636 patent/WO2002036144A1/en not_active Ceased
- 2001-10-26 US US10/415,519 patent/US7498303B2/en not_active Expired - Fee Related
- 2001-10-26 AU AU2001295359A patent/AU2001295359A1/en not_active Abandoned
- 2001-10-26 EP EP01975948A patent/EP1330257B1/de not_active Expired - Lifetime
- 2001-10-26 CA CA002427731A patent/CA2427731A1/en not_active Abandoned
- 2001-10-26 BR BR0115067-7A patent/BR0115067A/pt not_active Application Discontinuation
-
2009
- 2009-01-20 US US12/356,406 patent/US20090246209A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004512369A (ja) | 2004-04-22 |
| DE60113142T2 (de) | 2006-07-06 |
| EP1330257B1 (de) | 2005-08-31 |
| US20040023878A1 (en) | 2004-02-05 |
| CA2427731A1 (en) | 2002-05-10 |
| AU2001295359A1 (en) | 2002-05-15 |
| US20090246209A1 (en) | 2009-10-01 |
| DE60113142D1 (de) | 2005-10-06 |
| EP1330257A1 (de) | 2003-07-30 |
| WO2002036144A1 (en) | 2002-05-10 |
| BR0115067A (pt) | 2004-04-06 |
| US7498303B2 (en) | 2009-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE303156T1 (de) | Verwendung von gnrh-analogue zur behandlung der harninkontinenz | |
| IL138979A0 (en) | Use of cannabinoids as anti-inflammatory agents | |
| DE69618787D1 (de) | Topische zusammensetzungen mit verbessertem hautgefühl | |
| ATE289781T1 (de) | Schlinge mit polsterung zur behandlung von harninkontinenz | |
| DK0755249T3 (da) | Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom | |
| ATE390928T1 (de) | Zusammensetzungen zur behandlung von hauterkrankungen | |
| DK1204335T3 (da) | Fremgangsmåde til at forskønne formen af en menneskekrop ved hjælp af et kosmetisk plaster | |
| ATE214272T1 (de) | Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz | |
| ATE359808T1 (de) | Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma | |
| ATE234614T1 (de) | Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren | |
| TR200200278T2 (tr) | Kalsilitik bileşimler | |
| DE60023139D1 (de) | Verwendung von il6r- il6 chimären für die behandlung von neurodegenerativen erkankungen | |
| DE50106546D1 (de) | Zubereitung von cimicifuga racemosa zur behandlung der inkontinenz | |
| DK1244438T3 (da) | Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde | |
| DE60119285D1 (de) | Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall | |
| ID27755A (id) | Komposisi parfum | |
| ATE458495T1 (de) | Therapeutische zubereitung für autoimmune erkrankungen | |
| ATE278401T1 (de) | Verwendung von riluzol zur behandlung von akustischen traumazuständen | |
| ATE236633T1 (de) | Topische verwendung von loperamid zur behandlung mikrobieller infektionen | |
| ATE345121T1 (de) | Verwendung von konjugierter linolsäure zur behandlung der erkältung | |
| WO2002034210A3 (fr) | Utilisation de l'association d'au moins un carotenoide et de vitamine c pour traiter les signes cutanes du vieillissement | |
| ATE291425T1 (de) | R-eliprodil zur behandlung von glaucoma | |
| AU8988901A (en) | Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) for treating excess of glucocorticoids | |
| DE50202941D1 (de) | Verwendung von extrakten aus cimicifuga-arten als organselektives arzneimittel zur behandlung von sexualhormonabhängigen erkrankungen des urogenitaltraktes | |
| DE60210313D1 (de) | Verwendung von dattelkern-extrakt zur minderung der anzeichen der hautalterung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |